TESRIVETCEL
UNII 5V2WV5E8ZJ

Substance Identification & Data

This profile provides standardized clinical and technical data for Tesrivetcel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 5V2WV5E8ZJ.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

5V2WV5E8ZJ

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TESRIVETCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C203131

National Cancer Institute reference terminology for clinical and research data.

INN ID

12665

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180691

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9796

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tesrivetcel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TESRIVETCEL

Common Names & Synonyms

EQUINE ALLOGENEIC TENOGENIC-PRIMED MESENCHYMAL STROMAL/STEM CELLS (MSCS), ISOLATED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) COLLECTED FROM DONOR HORSES. THE MSCS ARE SELECTED FOR BY GROWING THE PBMCS IN MEDIA CONTAINING FETAL BOVINE SERUM (FBS) AND DEXAMETHASONE. THE CELLS ARE THEN EXPANDED IN MEDIA CONTAINING FBS, AND PRIOR TO DIFFERENTIATION TOWARDS TENOCYTES BY GROWTH IN MEDIA CONTAINING FBS, FIBROBLAST-GROWTH FACTOR 2 (FGF-2) AND INSULIN-LIKE GROWTH FACTOR-1 (IGF-I). THE FINAL CELLS ARE CHARACTERIZED BY THEIR STRETCHED SPINDLE SHAPED MORPHOLOGY, AND BY EXPRESSION OF THE CELLULAR SURFACE MARKERS CD90 (>=95%) AND CD44 (>=85%) AND ABSENCE OF MHC CLASS II EXPRESSION (<=2%). THE CELLS SECRETE PROSTAGLANDIN E2 (PGE2) AND EXPRESS THE ACTIN ALPHA 2 (ACTA2) GENE (>2.3 FOLD)

TESRIVETCEL [INN]

External Clinical & Regulatory Resources

Previous UNII5V2TLQ4DUH

Next UNII5V2XJN3FRE